Major Force in the Personalized Cell Therapy Market 2025: Rising Neurological Disorders Fuel Growth In The Personalized Cell Therapy Market

How Will the Personalized Cell Therapy Market Grow, and What Is the Projected Market Size?
In recent times, the market size for personalized cell therapy has seen substantial growth. The market is predicted to expand from $17.11 billion in 2024, escalating to $21 billion in 2025, showing a compound annual growth rate (CAGR) of 22.8%. Factors like a surge in awareness about personalized medicine, an escalation in healthcare expenditure, growing government initiatives, increased funding for clinical trials, and a rising prevalence of neurological disorders have contributed to the growth observed in the past.

It is projected that the market size for personalized cell therapy will witness massive growth in the coming years. With an estimated compound annual growth rate (CAGR) of 22.4%, the market is anticipated to reach a value of $47.14 billion by 2029. This growth during the forecasted period could be due to several contributing factors such as the increase in clinical trials, the surge in chronic disease cases, an aging population, a high prevalence of cancer, and the widespread use of regenerative medicines. During this projected period, notable trends will likely include technological advancements, AI integration, personalized vaccines, the application of bioinformatics, and the use of microfluidic technologies.

What Key Elements Are Boosting Growth in the Personalized Cell Therapy Market?
The escalation in neurological ailments is anticipated to fuel the expansion of the personalized cell therapy market in the future. Neurological conditions include a variety of diseases that affect the brain, spinal cord, and nerves, leading to symptoms like motor function impairment, cognitive degradation, and sensory abnormalities. These disorders are arising due to factors like an aging population, environmental stressors, and lifestyle modifications which all contribute to an increase in neurodegenerative diseases. Personalized cell therapy is crucial for these neurological conditions because it provides custom treatments that cater to particular patient requirements, potentially rejuvenating damaged neural tissue and enhancing outcomes in intricate, individualized conditions. To illustrate, in December 2022, the Parkinson Foundation, an organization from the US government, reported that the annual occurrence of Parkinson's disease (PD) among older people is 50% more than the current approximation of 60,000 cases. Moreover, it's forecasted that by 2030, an additional 1.2 million Americans will develop Parkinson's disease. As a result, the escalating incidences of neurological disorders are fuelling the growth of the personalized cell therapy market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19137&type=smp

Who Are the Major Industry Players Fueling Personalized Cell Therapy Market Expansion?
Major companies operating in the personalized cell therapy marker are AbbVie Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences Inc., Cipla Limited, Poseida Therapeutics Inc., Sangamo Therapeutics Inc., Nkarta Therapeutics Inc., Intellia Therapeutics Inc., Tessa Therapeutics Pte Ltd., Atara Biotherapeutics Inc., Adaptimmune Therapeutics plc, Precision BioSciences Inc., Editas Medicine Inc., Cellectis S.A., Gracell Biotechnologies Inc., Mesoblast Limited, Fate Therapeutics Inc., Athersys Inc., Bellicum Pharmaceuticals Inc., Celyad Oncology SA, Century Therapeutics Inc., Gamida Cell Ltd., CRISPR Therapeutics AG, Allogene Therapeutics Inc.

Which Key Developments Are Influencing the Personalized Cell Therapy Market?
Key players in the personalized cell therapy market primarily concentrate on forging strategic alliances, allowing them to fast-track the production and launch of breakthrough treatments. Such cooperative agreements amalgamate resources, proficiency, and technology, leading to enhanced R&D capabilities, efficient clinical trials conduct, and a smoother journey through regulatory procedures. To illustrate, Century Therapeutics Inc., a U.S. biotech firm, and Bristol Myers Squibb (BMS), a U.S. biopharmaceutical firm, joined forces in October 2022 in order to evolve and market allogeneic cell treatments. Their collaboration features the usage of Century's groundbreaking induced pluripotent stem cell (iPSC) technology to develop engineered natural killer (NK) and T cell treatments for hematologic malignancies and solid tumors. In their agreement, they have included the evolution of up to four unique cell therapy plans, with an initial spotlight on two particular sections: acute myeloid leukemia (AML) and multiple myeloma. These projects will involve the use of engineered NK cells or gamma delta T cells obtained from iPSCs.

How Is the Segmentation of the Personalized Cell Therapy Market Defined?
The personalized cell therapymarket covered in this report is segmented -

1) By Cell Type: Lymphocytes, Mesenchymal Stem Cell, Hematopoietic Stem Cell, Other Cell Type
2) By Technique: Platelet Transfusions, Bone Marrow Transplantation, Packed Red Cell Transfusions, Organ Transplantation
3) By Application: Cardiovascular Diseases, Neurological Disorders, Inflammatory Diseases, Diabetes, Cancer, Other Applications
4) By End-User: Hospital, Homecare, Specialty Clinics, Other End-User

Subsegments:
1) By Lymphocytes: T Cells, Natural Killer (NK) Cells, Regulatory T Cells
2) By Mesenchymal Stem Cells (MSCs): Bone Marrow-Derived MSCs, Adipose Tissue-Derived MSCs, Umbilical Cord-Derived MSCs
3) By Hematopoietic Stem Cells: Autologous Hematopoietic Stem Cells, Allogeneic Hematopoietic Stem Cells
4) By Other Cell Types: Dendritic Cells, Fibroblasts, Endothelial Cells

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/personalized-cell-therapy-global-market-report

What Is the Leading Region in the Personalized Cell Therapy Market?
North America was the largest region in the personalized cell therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cell therapy marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Personalized Cell Therapy Global Market Report?

- Market Size Analysis: Analyze the Personalized Cell Therapy Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Personalized Cell Therapy Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Personalized Cell Therapy Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Personalized Cell Therapy Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19137

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.